Saturday, July 11, 2026

pharma · Head and Neck Neoplasms · Rheumatoid Arthritis

Chinese University of

Chinese University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Head and Neck Neoplasms, Rheumatoid Arthritis, Rare Tumor, Essential Hypertension, Primary Esophageal Motility D

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
42
Drugs
55
Patents
0
Clinical program

Telbivudine

Unknown · small molecule · Chronic Hepatitis B

Telbivudine for Chronic Hepatitis B is a Unknown program (small_molecule) at Chinese University of Hong Kong with 1 ClinicalTrials.gov record(s).

← All Chinese University of Hong Kong projects Unknown small molecule terminated

Internal code Telbivudine for CKD

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Chinese University of Hong Kong
Phase
Unknown
Modality
small_molecule
Indication
Chronic Hepatitis B
Status
terminated
Trials
1